BioAge has begun Phase 2 QUELL-CV trial, testing whether NLRP3 inhibition eases cardiovascular inflammatory burden.
Inflammation has become something of a recurring character in geroscience. Whether researchers are studying cardiovascular disease, retinal disorders or neurodegeneration, the same chronic, low-grade immune activity keeps appearing in the background – less an innocent bystander than an increasingly persuasive suspect. Turning that observation into medicines that genuinely alter the course of aging, however, is quite another matter.
BioAge Labs is hoping to do precisely that. Recently, the company announced that the first participant has been dosed in QUELL-CV, a randomized Phase 2 proof-of-concept trial evaluating BGE-102 – its once-daily oral inhibitor of the NLRP3 inflammasome – in adults with elevated systemic inflammation and increased cardiovascular risk. Rather than being powered to measure cardiovascular outcomes directly, the study is designed to establish dose-response relationships using changes in high-sensitivity C-reactive protein (hsCRP) as its primary endpoint, while also examining a broader panel of inflammatory and cardiometabolic biomarkers ahead of potential Phase 3 development.
Longevity.Technology: One of the enduring frustrations in geroscience is that while the hallmarks of aging are increasingly well described, proving that modifying one of them translates into meaningful clinical benefit has proved considerably harder. Chronic inflammation – or inflammaging – has long occupied a starring role in the aging narrative, implicated in everything from cardiovascular disease to neurodegeneration, yet demonstrating that dampening this persistent inflammatory background can alter the trajectory of aging rather than simply treating the symptoms of individual diseases remains the challenge. That makes BioAge’s latest clinical milestone interesting for reasons that extend beyond cardiovascular risk; discovered through analysis of human longevity datasets rather than conventional disease biology, BGE-102 represents an approach that starts with the biology of healthy aging and works forwards to disease, rather than the other way around. That distinction may sound subtle, but if the same mechanism ultimately proves beneficial across multiple age-related conditions, it would strengthen the argument that we are beginning to target shared aging biology rather than a collection of unrelated pathologies – a prospect that has tantalized geroscientists for decades. Of course, lowering hsCRP is not the finish line; biomarkers, however encouraging, are not synonymous with improved healthspan. Still, the field has reached the point where the most interesting longevity drugs are no longer asking whether aging biology matters – they are asking whether it can finally be translated into medicines that physicians might one day prescribe before disease takes hold. Now there’s a thought.
To find out more about why BioAge believes targeting inflammaging could have implications well beyond cardiovascular disease – and why human longevity data are changing the way the company discovers medicines – we sat down with cofounder and CEO Dr Kristen Fortney.
Designed around human aging
Unlike many drug discovery programs, BioAge did not arrive at NLRP3 by beginning with cardiovascular disease. Instead, BioAge’s discovery platform uncovered the target through analysis of human aging cohorts, comparing people who age more successfully with those who do not before asking where those biological pathways might have therapeutic relevance.
“Most drug discovery starts with a disease and works backward to a target, and a lot of those targets look great in a mouse and then don’t hold up in people,” explains Fortney. “We start from the other end. We look at large human datasets of people aging at different rates, and ask what’s actually different in the ones who stay healthy. So by the time we’re investing in a molecule, the target already has human evidence behind it, rather than a hypothesis we’re hoping will translate from animals.”
The result was NLRP3, an inflammasome complex increasingly implicated in chronic age-related inflammation. According to Fortney, reduced NLRP3 activity tracked with longer, healthier lives in the human datasets that informed the company’s discovery platform – providing the rationale for developing BGE-102.
Looking beyond cardiovascular disease
QUELL-CV is evaluating BGE-102 in approximately 160 adults with obesity, elevated systemic inflammation and at least one additional cardiovascular risk factor, using reductions in high-sensitivity C-reactive protein as its primary endpoint. The study is intended to establish the optimal dose for later-stage development, while also examining a broader panel of inflammatory and cardiometabolic biomarkers.
Choosing cardiovascular disease as the lead indication reflects a broader change in thinking, Fortney argues, as inflammation increasingly becomes a therapeutic target in its own right rather than simply a consequence of disease.
“Inflammation is increasingly recognized as a major modifiable driver of cardiovascular events, on par with elevated LDL cholesterol – and an oral therapy that addresses it could transform care and outcomes the way statins did decades ago,” she says.
“Our recently reported Phase 1 results positioned BGE-102 as a potential best-in-class NLRP3 inhibitor, with profound hsCRP reductions on a well-tolerated, once-daily oral dose. QUELL-CV will inform optimal dose selection in Phase 3 and BGE-102’s path forward in cardiovascular disease. With a second proof-of-concept study in diabetic macular edema planned to start mid-2026, we are positioned to demonstrate BGE-102’s broad potential.”
For BioAge, however, cardiovascular disease represents only the first test of a broader hypothesis.
“Inflammaging is one of the core hallmarks of aging. It’s not a feature of any one disease, it’s part of how we age – so if you can turn it down, you could potentially help across a lot of age-related diseases at once,” says Fortney. “We’re currently developing BGE-102 in cardiovascular risk with QUELL-CV and, later this year, also in diabetic macular edema. If one molecule delivers clinically in diseases that look nothing alike, that’s the real signal we’re modifying the underlying aging biology and not just treating one condition.”
The second indication is no accident. Although cardiovascular disease and diabetic macular edema appear clinically unrelated, both are increasingly linked to inflammatory mechanisms associated with aging. Demonstrating efficacy in both settings would strengthen the case that NLRP3 inhibition is acting on a shared biological process rather than a disease-specific pathway.
A preventive future
Should therapies targeting chronic inflammation ultimately prove capable of delaying disease onset, their role could extend well beyond treating established pathology – an idea that resonates strongly with the ambitions of geroscience.
“I do think that’s where it could end up, and that’s what excites me,” says Fortney. “If inflammation is central to aging, the time to turn it down is early, before any one disease takes hold. Inflammation could get there the same way cholesterol did: cholesterol became something we treat preventively because statins gave us an oral therapy to lower it, and because it gave us a simple number that told us who to treat and whether the drug was working.”
For Fortney, high-sensitivity C-reactive protein could eventually occupy a similar position, although she is quick to acknowledge the scale of evidence still required.
“For inflammation, we think that number could be hsCRP. And getting there will take the same thing it took for cholesterol and statins: years of data showing that turning inflammation down actually prevents disease.”
One target, many diseases
Whether NLRP3 inhibition ultimately proves capable of modifying human aging remains an open question, and one that no single trial can answer. Yet as longevity biotechnology matures, studies such as QUELL-CV reflect a broader shift in thinking – away from treating age-related diseases as isolated conditions and towards testing whether intervening in the biology they share might one day keep several of them at bay. Ambitious? Certainly. After all, biology has an irritating habit of being more complicated than our hypotheses. The encouraging part is that the field is finally beginning to ask those hypotheses questions that only clinical trials can answer.
